全身麻醉药物遗传药理学研究进展

doi:10.12092/j.issn.1009-2501.2018.02.019

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (2): 217-222.doi: 10.12092/j.issn.1009-2501.2018.02.019

全身麻醉药物遗传药理学研究进展

谢商宸^1,2，李玮^1,2，廖萍^1,2，贺毅憬^1,2，Howard L. Mcleod ^1,2

¹中南大学湘雅医院临床药理研究所，长沙 410008，湖南; ²中南大学临床药理研究所,遗传药理学湖南省重点实验室，长沙 410078，湖南

收稿日期:2017-11-07 修回日期:2018-01-05 出版日期:2018-02-26 发布日期:2018-03-02
通讯作者: Howard L. Mcleod，男，博士生导师，研究方向: 遗传药理学和临床药理学。 Tel: 0731-84805380 E-mail: Howard.McLeod@moffitt.org
作者简介:谢商宸，男，硕士研究生，研究方向: 遗传药理学和临床药理学。 Tel: 0731-84805380 E-mail: xsc874067105@gmail.com
基金资助:
国家自然科学基金（81403022，81673517，81773821）

Research progress of general anesthesia in the pharmacogenetics

XIE Shangchen ^1,2, LI Wei ^1,2, LIAO Ping ^1,2, HE Yijing ^1,2, MCLEOD Howard L.^1,2

¹ Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; ² Institute of Clinical Pharmacology Central South University,Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China

Received:2017-11-07 Revised:2018-01-05 Online:2018-02-26 Published:2018-03-02

摘要/Abstract

摘要：

全身麻醉是指由多种全身麻醉药物引起的一系列无意识、记忆缺失、痛觉缺失、运动不能等状态。随着遗传药理学及药物基因组学的发展，全身麻醉中各类药物与自身遗传因素的关系越来越受到关注。本文对全身麻醉中常用的镇痛药、镇静催眠药、肌松药及止吐药的遗传药理学研究进行综述，归纳近年来的研究进展。

关键词: 全身麻醉, 遗传药理学, 药物基因组学

Abstract:

General anesthesia is a state of unconsciousness, amnesia, analgesia and akinesia induced by drugs used in general anesthesia. Along with the development of pharmacogenetics and pharmacogenomics, pharmacogenetic studies of these drugs have been carried out continuously. This review summarizes the pharmacogenetics of commonly used general anesthesia drugs like analgesics, sedative-hypnotics, neuromuscular blockers and antiemetics in recent years.

Key words: general anesthesia, pharmacogenetics, pharmacogenomics

中图分类号:

R968

谢商宸，李玮，廖萍，贺毅憬，Howard L. Mcleod. 全身麻醉药物遗传药理学研究进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 217-222.

XIE Shangchen, LI Wei, LIAO Ping, HE Yijing, MCLEOD Howard L.. Research progress of general anesthesia in the pharmacogenetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 217-222.

参考文献

［1］Brown EN, Lydic R, Schiff ND.General anesthesia, sleep, and coma［J］. N Engl J Med, 2010, 363(27): 2638-2650.
［2］Sadhasivam S, Chidambaran V, Zhang X, et al. Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics ［J］. Pharmacogenomics J, 2015, 15(2): 119-126.
［3］Bastami S, Gupta A, Zackrisson AL, et al. Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption ［J］. Basic Clin Pharmacol Toxicol, 2014, 115(5): 423-431.
［4］Matic M, Simons SH, van Lingen RA, et al. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype ［J］. Pharmacogenomics, 2014, 15(10): 1287-1295.
［5］Venkatasubramanian R, Fukuda T, Niu J, et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children ［J］. Pharmacogenomics, 2014, 15(10): 1297-1309.
［6］付孟龙, 周宏灏. MDR1基因多态性及其临床相关性［J］. 中国临床药理学与治疗学, 2016, 21(4): 463-469.
［7］Lee MG, Kim HJ, Lee KH,et al. The influence of genotype polymorphism on morphine analgesic effect for postoperative pain in children ［J］. Korean J Pain, 2016, 29(1): 34-39.
［8］Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia ［J］. Anesthesiology, 2008, 109(3): 520-526.
［9］Nielsen LM, Sverrisdóttir E, Stage TB, et al. Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics ［J］. Eur J Pharm Sci, 2017, 99:337-342.
［10］Tzvetkov MV, dos Santos Pereira JN, Meineke I, et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration ［J］. Biochem Pharmacol, 2013, 86(5): 666-678.
［11］Dean L. Codeine therapy and CYP2D6 genotype［M］ //Pratt V, Mcleod H, Dean L, et al. Medical genetics summaries. Bethesda (MD). 2012.
［12］Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism ［J］. N Engl J Med, 2004, 351(27): 2827-2831.
［13］Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death ［J］. N Engl J Med, 2009, 361(8): 827-828.
［14］Friedrichsdorf SJ, Nugent AP, Strobl AQ. Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports ［J］. J Opioid Manag, 2013, 9(2): 151-155.
［15］Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update［J］. Clin Pharmacol Ther, 2014, 95(4): 376-382.
［16］Baber M, Chaudhry S, Kelly L, et al. The pharmacogenetics of codeine pain relief in the postpartum period ［J］. Pharmacogenomics J, 2015, 15(5): 430-435.
［17］Bell GC, Donovan KA, Mcleod HL. Clinical implications of opioid pharmacogenomics in patients with cancer ［J］. Cancer Control, 2015, 22(4): 426-432.
［18］Tanaka N, Naito T, Yagi T, et al. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period［J］.Ther Drug Monit, 2014, 36(3): 345-352.
［19］Ishida T, Naito T, Sato H, et al. Relationship between the plasma fentanyl and serum 4beta-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain ［J］. Drug Metab Pharmacokinet, 2016, 31(3): 242-248.
［20］Koolen SL, Van der Rijt CC. Is there a role for pharmacogenetics in the dosing of fentanyl ［J］ ? Pharmacogenomics, 2017, 18(5): 417-419.
［21］Mieda T, Nishizawa D, Nakagawa H, et al. Genome-wide association study identifies candidate loci associated with postoperative fentanyl requirements after laparoscopic-assisted colectomy ［J］. Pharmacogenomics, 2016, 17(2): 133-145.
［22］Hohmann N, Kocheise F, Carls A, et al. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans ［J］. Br J Clin Pharmacol, 2015, 79(2): 278-285.
［23］Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients ［J］. J Clin Pharmacol, 2014, 54(2): 215-224.
［24］De Jonge H, Elens L, de loor H, et al. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients ［J］. Pharmacogenomics J, 2015, 15(2): 144-152.
［25］Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin ［J］. Pharmacogenet Genomics, 2013, 23(3): 148-155.
［26］Mikstacki A, Skrzypczak-Zielinska M, et al. The impact of genetic factors on response to anaesthetics ［J］. Adv Med Sci, 2013, 58(1): 9-14.
［27］Mourao AL, DE abreu FG, Fiegenbaum M. Impact of the cytochrome P450 2B6 (CYP2B6) gene polymorphism c.516G>T (rs3745274) on propofol dose variability ［J］. Eur J Drug Metab Pharmacokinet, 2016, 41(5): 511-515.
［28］Eugene AR.CYP2B6 genotype guided dosing of propofol anesthesia in the elderly based on nonparametric population pharmacokinetic modeling and simulations［J］. Int J Clin Pharmacol Toxicol, 2017, 6(1): 242-249.
［29］Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia ［J］. Science, 1991, 253(5018): 448-451.
［30］Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review ［J］. Orphanet J Rare Dis, 2015, 10: 93.
［31］Alvarellos ML, McDonagh EM, Patel S, et al.PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics ［J］. Pharmacogenet Genomics, 2015, 25(12): 622-630.
［32］Garcia DF, Oliveira TG, Molfetta GA, et al. Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine ［J］. Genet Mol Biol, 2011, 34(1): 40-44.
［33］Gatke MR, Bundgaard JR, Viby-mogensen J. Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia ［J］. Pharmacogenet Genomics, 2007, 17(11): 995-999.
［34］Wichmann S, Faerk G, Bundgaard JR, et al. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene ［J］. Pharmacogenet Genomics, 2016, 26(7): 351-356.
［35］Costa CC, Coelho EB, Lanchote VL, et al. The SLCO1A2 -189-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries ［J］. Eur J Clinl Pharmacol, 2017, 73(8): 957-963.
［36］Mei Y, Wang SY, Li Y, et al. Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients ［J］. J Clin Pharmacol, 2015, 55(3): 261-268.
［37］Bell GC, Caudle KE, Whirl-carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron ［J］. Clin Pharmacol Ther, 2017, 102(2): 213-218.
［38］He H, Yin JY, Xu YJ, et al. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting ［J］. Clin Ther, 2014, 36(8): 1242-1252 e2.
［39］Farhat K, Iqbal J, Waheed A, et al.Association of anti-emetic efficacy of ondansetron with G2677T polymorphism in a drug transporter gene ABCB1 in pakistani population ［J］. J Coll Physicians Surg Pak, 2015, 25(7): 486-490.
［40］Farhat K, Waheed A, Hussain A, et al. Influence of genetic variations in ABCB1 on the clinical efficacy of ondansetron- A pharmacogenetic analysis of Pakistani population ［J］［J］. J Pak Med Assoc, 2015, 65(9): 963-966.
［41］郭成贤, 王晶, 李金高, 等.临床药物基因组学应用现状［J］.中国临床药理学与治疗学, 2016, 21(4): 458-462.

[1]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[2]	孙媛媛, 邓锟红, 王思懿, 况赟, 邹婵, 郭成贤, 何庆南, 刘和林, 阳国平. 个体化用药基因电子身份应用程序的设计与实现[J]. 中国临床药理学与治疗学, 2022, 27(3): 274-280.
[3]	杨杰, 曹君利, 刘鹤. 无创神经调控技术对全麻患者术后睡眠功能紊乱影响的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1322-1332.
[4]	倪渊博, 张昕, 李仪, 刘存明. 麻醉及镇痛药物与认知功能[J]. 中国临床药理学与治疗学, 2022, 27(12): 1365-1374.
[5]	丁加慧, 周瑜, 袁天杰, 夏俊明, 李文献, 韩园. 麻醉相关神经网络在麻醉深度监测中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1400-1407.
[6]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[7]	金宝伟, 蒋宗明, 郭建荣. 瑞马唑仑的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1444-1448.
[8]	梅笛, 沈纪中, 刘春妍, 陆程灿, 徐伟, 彭宇竹. 新型口服抗凝药的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1200-1207.
[9]	徐薇，曲卫敏，洪宗元. 特异性操控神经元活性法研究全麻药作用机制的进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 825-829.
[10]	郭成贤，王晶，李金高，袁洪，周宏灏，阳国平. 临床药物基因组学应用现状[J]. 中国临床药理学与治疗学, 2016, 21(4): 458-462.
[11]	赵德恒, 萧惠来. FDA对药物基因组学早期临床研究的建议[J]. 中国临床药理学与治疗学, 2015, 20(2): 208-212.
[12]	刘舒，郑玲杰，谭志荣. 寡肽转运体PepT1的遗传药理学研究进展[J]. 中国临床药理学与治疗学, 2015, 20(11): 1315-1320.
[13]	张月丽, 明英姿, 周宏灏, 张伟. 他克莫司:药代动力学,药效动力学和药物基因组学[J]. 中国临床药理学与治疗学, 2014, 19(9): 1042-1049.
[14]	郑艺, 尹继业, 周宏灏, 刘昭前. 基因多态性与铂类药物毒性反应研究进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1051-1056.
[15]	吴嗣莲, 陈永权, 金孝岠. 复方利多卡因乳膏对小儿腹部手术全麻拔管的影响[J]. 中国临床药理学与治疗学, 2014, 19(7): 801-804.

全身麻醉药物遗传药理学研究进展

Research progress of general anesthesia in the pharmacogenetics

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价